ZINACEF

This brand name is authorized in Brazil, Cyprus, Estonia, Finland, Hong Kong SAR China, Ireland, Israel, Lithuania, Malta, New Zealand, Poland, South Africa, UK.

Active ingredients

The drug ZINACEF contains one active pharmaceutical ingredient (API):

1	Cefuroxime UNII R8A7M9MY61 - CEFUROXIME SODIUM
	Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.
	Read more about Cefuroxime

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ZINACEF Powder for injection / infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01DC02	Cefuroxime	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01D Other beta-lactam antibacterials → J01DC Second-generation cephalosporins
Discover more medicines within J01DC02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	510609001158311
EE	Ravimiamet	1007031, 1007064
FI	Lääkealan turvallisuus- ja kehittämiskeskus	041013, 058966, 116046
GB	Medicines & Healthcare Products Regulatory Agency	39394, 45305, 47403
HK	Department of Health Drug Office	07013, 07014, 07015
IE	Health Products Regulatory Authority	55735, 82384
IL	מִשְׂרַד הַבְּרִיאוּת	3410
LT	Valstybinė vaistų kontrolės tarnyba	1015682, 1015683, 1017924
MT	Medicines Authority	MA685/04301, MA685/04302
NZ	Medicines and Medical Devices Safety Authority	2782, 2783
PL	Rejestru Produktów Leczniczych	100074314, 100074320
ZA	Health Products Regulatory Authority	L/20.1.1/0096, L/20.1.1/0097